Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7198457 (autogene cevumeran) + pembrolizumab vs pembrolizumab in untreated advanced melanoma
2023-507389-15-00Phase 2Completed
- Sponsor
- Genentech
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial in melanoma comparing autogene cevumeran + pembrolizumab with pembrolizumab monotherapy (2 arms). Primary endpoint: Progression Free Survival. Started May 2024; status: completed.
02
Drugs
pembrolizumabautogene cevumeran
03
Conditions
melanoma
Beyond the preview
Go deeper on 2023-507389-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507389-15-00.